Skip to main content

Table 1 Patient demographics

From: New transperineal ultrasound-guided biopsy for men in whom PSA is increasing after Miles’ operation

Patient No

Age

PSA (ng/mL)

Prostate volume (mL)

PSAD (ng/mL2)

Biopsy (year)

3 T MRI

TPUS

Scanner

Coil

Scanner

Probe

1

71

23.61

21.1

1.12

2009

Achieva (PH)

Surface

IU 22 (PH)

C9 5ec (PH)

2

77

6.19

92.1

0.07

2012

Achieva (PH)

Surface

IU 22 (PH)

C9 5ec (PH)

3

70

11.92

19.4

0.61

2016

Skyra (SH)

Surface

IU 22 (PH)

C9 5ec (PH)

4

72

22.60

19.8

1.14

2017

Achieva (PH)

Surface

IU 22 (PH)

C9 5ec (PH)

5

66

25.29

17.4

1.45

2019

Achieva (PH)

Surface

IU 22 (PH)

C9 5ec (PH)

6

78

22.69

27.8

0.82

2020

Achieva (PH)

Surface

EPIC (PH)

C10 4ec (PH)

7

71

11.70

56.3

0.21

2020

Ingenia CX (PH)

Surface

EPIC (PH)

C10 4ec (PH)

8

64

69.70

26.8

2.60

2021

Ingenia CX (PH)

Surface

EPIC (PH)

C10 4ec (PH)

9

61

10.10

53.0

0.19

2022

Magnetom Vida (SH)

Surface

EPIC (PH)

C10 4ec (PH)

  1. No., number; PSA, prostate-specific antigen; PSAD, prostate-specific antigen density; MRI, magnetic resonance imaging; TPUS, transperineal ultrasound; PH, Philips Healthcare; SH, Siemens Healthcare